Methamphetamine Use and Affective Disorders

Methamphetamine Use and Affective Disorders

Larissa Mooney, MD

UCLA ISAP, UCLA Division of Addiction Psychiatry

Tuesday, October 12th, 2021

We respectfully acknowledge that we live and work in territories where Indigenous nations and Tribal groups are traditional stewards of the land.

Please join us in supporting efforts to affirm Tribal sovereignty across what is now known as California and in displaying respect, honor and gratitude for all Indigenous people.

Indigenous Land Acknowledgement

Whose land are you on? Option 1: Text your zip code to 1-855-917-5263Option 2: Enter your location at https://native-land.caOption 3: Access Native Land website via QR Code:

Methamphetamine Use and Affective Disorders

Larissa Mooney, MDAssociate Clinical Professor of Psychiatry, UCLA

Director, UCLA Division of Addiction Psychiatry

October 12th, 2021

Disclosures

There are no relevant financial relationships with

ACCME-defined commercial interests for anyone who

was in control of the content of this activity.

Outline

• Methamphetamine Use Epidemiology and Clinical Effects

• Behavioral and Medication Treatments (off-label) for MUD

• Mood D/O Comorbidity:

– Bipolar Spectrum D/O and SUDs

– Major Depressive D/O and SUDs

• Concluding thoughts

7

Amphetamine-Type Stimulants

Amphetamine

―Powder, Tablets, Liquid

―Routes of administration: oral, inhalation, injection, smoking

Methamphetamine (more potent)

―Powder: inhaled, smoked, injected

―Crystal/Ice: smoked

―Tablets: oral, crushed and inhaled, smoked, injected

Approximately 40-60 million users worldwide

“Crystal Meth” or “Ice”

• Most potent, pure and distilled type of meth

– More intense physiologic and behavioral effects

– Greater dopamine release than powdered meth

• More addictive potential

• Shaped in the form of crystalline rocks

– Commonly smoked but can be injected too

• “Ice” turns to liquid once heated

• Most illicit methamphetamine used in the U.S. is crystal meth

9

Methamphetamine Use Among Treatment-Seeking Opioid Users

Ellis, Kasper & Cicero, 2018, Drug Alcohol Depend.

U.S. Stimulant Overdoses

From 2009-2018 there was an 8x increase in the

overdose death rate involving psychostimulants

(from 0.5 to 3.9 per 100,000)

Methamphetamine: chemical structure

• Exists as 2 enantiomers: levo (L) and dextro (D)

• Methamphetamine proper refers to racemic form (equal

amounts)

• Potency refers to % of drug that is the D-isomer 13

Early 2000s methamphetamine

• At its height in the 2000s, meth was primarily being made in home labs using the OTC nasal decongestant ingredient pseudoephedrine

14

• Subsequently laws were enacted to limit sale of pseudoephedrine

The P2P Method

• Manufacturers/chemists begin using different formula to make meth without pseudoephedrine

– 1-phenyl-2-propanone (P2P)

– Altered ratio of L- to D-meth

15

• DEA profiling program:

In 2010 43% seized meth

made using P2P

In 2011 79%

In 2013 95%

Methamphetamine seizures

16

Today U.S. border agents are seizing 10-

20x the amount of meth they did in 2010

Stoddard M and Alamdari N. “As nation faces opioid epidemic, in Nebraska and Iowa, meth is still the “No 1 threat.” Omaha World Herald. Oct 9, 2017. Accessed 10/16/2019.

Available at: https://www.omaha.com/news/crime/as-nation-faces-opioid-epidemic-in-nebraska-and-iowa-meth/article_87acfe3a-4708-5207-9271-3a158dc66ece.html

Purity of Mexican-produced meth has surged from 39% in 2007 to 97% today

17The Economist. Amid the opioid crisis, a different drug comes roaring back. March 9, 2019. Accessed October 11, 2019. Available at:

https://www.economist.com/united-states/2019/03/09/amid-the-opioid-crisis-a-different-drug-comes-roaring-back

Meth 2.0

Methamphetamine Mechanism of Action

•synthetic

•high lasts 8-24 hours

•T ½: 12 hours

•mechanism: increased catecholamines, DA

•limited medical uses

•Desoxyn

•neurotoxicity

(A)↓Dopamine transporters:

↓Ability to respond to non-drug rewards,

↑impulsivity, favor immediate > delayed reward

Volkow ND, Am J Psychiatry. 2001;158(3):377-382. © Copyright AAAP 2021

22

Stimulant use associated with

dysfunction in brain dopamine and

glutamate systems

Nora D. Volkow et al. J. Neurosci. 2001;21:9414-9418

©2001 by Society for Neuroscience

23

Recovery of Dopamine Transporters

with Abstinence

Clinical effects: short term

• Euphoria and “rush”

• Increased arousal

– ↑attention, ↑activity, ↑wakefulness, ↓fatigue, ↑libido

• Appetite suppression

• Autonomic and cardiovascular activation

– ↑respiration, ↑HR, ↑BP, arrhythmias, hyperthermia

• Psychiatric symptoms

– Psychosis, mood disturbances, anxiety24

Psychiatric effects of methamphetamine use

• Transient psychosis (up to 40%)

– Paranoia

– Delusions

– Visual, tactile, auditory hallucinations

– Ideas of reference

• Mood disturbances

– Depression, suicidality

– Hypomanic sx’s (e.g. racing thoughts, impulsivity)

• Anxiety, irritability

• Agitation, aggressive behavior

25

Co-occurring disorders: common and complex

Primary Psychiatric Disorder

+Methamphetamine Use Disorder

Methamphetamine-induced psychiatric disorder

Psychiatric and Substance Use Disorder (SUD) Comorbidity• Individuals with lifetime mood or anxiety

disorder

– Approximately 20% with SUD

• Individuals with lifetime SUD

– 41% with mood disorder

– 30% with anxiety disorder

• Comorbidity rates higher in women with SUDs despite lower rates of SUDs than men

27Source: NESARC 2001-2002

Comorbidity Continued...

• 56% of patients with bipolar disorder (BP), and 46% of patients with schizophrenia have SUD compared to 15% of the general population.

– Higher for Bipolar I than Bipolar II

– Mixed episodes, rapid cycling subtypes more common

• 60+% of psychiatric inpatients have a current or previous SUD

• Estimated that up to 50% of patients with SUD may have a treatable psychiatric disorder.

28Source: SAMHSA, 2007

Challenges for Dually Diagnosed

• Patients with both mental illness and SUD are more likely to have

– greater illness severity

– poorer treatment (tx) adherence

than those with mental illness alone.1

• Due to complexities in patient populations, there is little consensus in the scientific literature on the best treatments.

– Co-occurring disorders often excluded from medication trials

• Ex: antidepressants have been associated with mixed substance use outcomes in those with depression in clinical trials.2,3

29Sources: 1. SAMHSA, 2007; 2. Agabio, Trogu & Pani, 2018 Cochrane Review; 3. Torrens et al., 2005

BEHAVIORAL TREATMENT INTERVENTIONS

Current Status of Treatment Approaches for Stimulant Use Disorder

• Contingency management unanimously supported in reviews (7 recent systematic reviews and meta-analyses) found to have best evidence of effectiveness.

• Including for stimulant use reduction in patients on medications for OUD

• Other approaches with less but clear evidence of support: Cognitive Behavioral Therapy (CBT) and Community Reinforcement Approach (CRA).

• Approach with evidence for treatment of a broad variety of SUD: Motivational Interviewing (MI).

• Approach with recent studies showing benefit to stimulant users: Physical Exercise (PE).

Source: AshaRani, PV, et al. 2020; Bolivar, et al., 2021; Rawson et al., 2015; Trivedi et al.,

Contingency Management

• A technique employing the systematic delivery of positive reinforcement for desired behaviors.

• In the treatment of stimulant use disorder, vouchers or gift cards can be “earned” for submission of methamphetamine-free urine samples or other behaviors that promote recovery (e.g., attendance at treatment sessions).

• Implementation examples: VA system, dHealth (app-based) platforms (e.g. reSET, Dynamicare)

PHARMACOTHERAPY

Medications for MUD - 1

Positive Signals• Bupropion (better in low severity users)1

• Mirtazapine2

• Naltrexone3,8

• Methylphenidate4

• d-amphetamine (craving/WD)5

• Topiramate (better if abstinent at tx entry)6

• Modafinil (better in hi-severity users)7

1Elkashef et al. 2008, Shoptaw et al., 2008; Heinzerling et al., 2014; Anderson et al., 2015; 2Colfax et al., 2012;

Coffin et al., 2020; 3Jayaram-Linstrom et al., 2008; 4Tiihonen et al., 2007; Ling et al., 2014; 5Galloway et al., 2011; 6Elkashef et al., 2011; 7Heinzerling et al., 2010; Anderson et al., 2012.8 8Trivedi et al., 2021

Medications for MUD - 2

Summary of Evidence – Methamphetamine •Underpowered studies, high attrition•Bupropion (300 mg/day) may be more effective in individuals

with lower use disorder severity •May be better in individuals with depression, males

• Low strength evidence that methylphenidate and topiramate may facilitate reduction in use • Topiramate better if negative urine screen at baseline• Standard dosing ranges generally studied •More recent evidence: mirtazapine (2nd trial), and combination

XR-NTX + bupropion XL

Chan B, Kondo K, et al., 2018. VA ESP Project #05-225.; Coffin et al., 2019; Trivedi et al., 2021 NEJM

Bipolar D/O and Substance Use Disorders

Bipolar D/O and SUDs

• High co-morbidity rates: comorbidity of SUD up to 60% in BP D/O (AUD 45%)

– greater severity of mood symptoms

• Rapid cycling

– increased suicide risk

– worse tx adherence

– greater EtOH withdrawal

– higher rates of hospitalization

• Recovery of SUD associated with improved mood sx’s and outcomes.

38Source: Camacho & Akiskal, 2005; Farren et al., 2012; Levin & Hennesey, 2004

Psychosocial Tx

Integrated group therapy (IGT) best studied and effective for tx of co-occurring SUD + BP Disorder (developed by Weiss and colleagues)

39Source: Gold et al., 2018

Evidence for Comorbidity Tx…

• Randomized, double blind trial of pts with stimulant use d/o and BP d/o (N=80), quetiapine vs. risperidone.

– Both associated with reduced mood sx’s and cravings, and this was associated with reduced stim use

• Open label study (N=15) cocaine use d/o w/ BP d/o, therapeutic doses of VPA associated with reduced cocaine use

40Sources: Salloum et al., 2007; Nejtek et al., 2008 Journal of Clin Psychiatry; Coles, Sasiadek & George, 2019 review

Depression and SUDs

Treatment of Depression in Patients with Alcohol or Other SUD (Meta-Analysis)

• 14 randomized, double-blind, placebo-controlled trials

– Participants with unipolar depression & SUD

• 8 studies alcohol, 4 studies OUD/methadone, 2 cocaine

• 5 studies of tricyclic antidepressants, 7 of SSRIs, 2 others

• N=848 participants

42Source: Nunes & Levin, JAMA 2004

Results:

• Antidepressant medication modestly effective for treatment of depressive disorders among patients with SUD

• Improvement in depressive sx’s is associated with reductions in substance use

– Studies with greater depression effect sizes showed reduced substance use

– Studies with lower depression effect sizes showed no reduction in substance use

• Diagnosis of depression after one week of abstinence was associated with greater antidepressant effect

43Source: Nunes & Levin, 2004

Depression and SUDs

Current recommendations that alcohol and SUD not be a barrier to treatment of depression

44Source: Agabio, Trogu & Pani, 2018 Cochrane Review

• Care is needed in diagnosis of depression: period of abstinence is preferred but not required

• Antidepressant treatment may have limited impact on alcohol and drug use (reduced amount vs. abstinence)

• Specific psychosocial or pharmacological interventions for addictive disorders will be necessary

Emerging Evidence for Repetitive Transcranial Magnetic Stimulation (rTMS) for Addiction

• rTMS of frontal brain regions produces a selective stimulation of hippocampal dopamine (DA) release

– Positioning DA as a key candidate neurotransmitter system directly and selectively modulated by rTMS

• Long-term neurophysiological changes induced by rTMS have the potential to affect behaviors relating to drug craving, and relapse.

• Innovative, safe and cost-effective for some SUDs

45Source: Diana et al., 2017

Effects of rTMS on Craving and Substance Consumption (Review and Meta-analysis)

• rTMS has been studied for substance cravings and use outcomes (mostly nicotine, some cocaine, EtOH).

– 26 RCTs

– N=748 patients

• rTMS appeared to have an acute effect on reducing craving and substance consumption in patients with SUD.

– Anti-craving effect may be associated with stimulation dose.

46Source: Zhang et al., 2019

Concluding Thoughts

47

Importance of good psychiatric

history and interview for

clinical symptoms, medication

history.

Psychosocial treatments/

adjuvant medications to target SUD are important in

those with CODs.

Evidence for BP d/o, ADHD, PTSD is

strongest —treatment of the

underlying psychiatric illness will improve the

SUD, even if active.

Integratedtreatment for

CODs preferred.

48

Thank you! Larissa Mooney, MD

lmooney@mednet.ucla.edu

All photos: Photograph © 2003 by Alan Nyiri, courtesy of the Atkinson Photographic Archive

Questions?

49

References• Agabio, R., Trogu, E., & Pani, P. P. (2018). Antidepressants for the treatment of people with co-occurring depression and alcohol dependence. In

Cochrane Database of Systematic Reviews (Vol. 2018, Issue 4). John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD008581.pub2

• Bolivar, H.A., Klemperer, E.M., Coleman, S.R., Skelly, J., & Higgins, S.T. (2021). Contingency management for patients receiving medications for opioid use disorder: A systematic review and meta-analysis. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2021.1969

• Brown, S. A., & Schuckit, M. A. (1988). Changes in depression among abstinent alcoholics. Journal of Studies on Alcohol, 49(5), 412–417. https://doi.org/10.15288/jsa.1988.49.412

• Camacho, A., & Akiskal, H. S. (2005). Proposal for a bipolar-stimulant spectrum: Temperament, diagnostic validation and therapeutic outcomes with mood stabilizers. Journal of Affective Disorders, 85(1–2), 217–230. https://doi.org/10.1016/j.jad.2003.10.014

• Coles, A. S., Sasiadek, J., & George, T. P. (2019). Pharmacotherapies for co‐occurring substance use and bipolar disorders: A systematic review. Bipolar Disorders, 21(7), 595–610. https://doi.org/10.1111/bdi.12794

• Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. American Journal of Psychiatry, 176(11), 923–930. https://doi.org/10.1176/appi.ajp.2019.18101123

• Diana, M., Raij, T., Melis, M., Nummenmaa, A., Leggio, L., & Bonci, A. (2017). Rehabilitating the addicted brain with transcranial magnetic stimulation. In Nature Reviews Neuroscience (Vol. 18, Issue 11, pp. 685–693). Nature Publishing Group. https://doi.org/10.1038/nrn.2017.113

• Dorus, W., Ostrow, D. G., Anton, R., Cushman, P., Collins, J. F., Schaefer, M., Charles, H. L., Desai, P., Hayashida, M., Malkerneker, U., Willenbring, M., Fiscella, R., & Sather, M. R. (1989). Lithium Treatment of Depressed and Nondepressed Alcoholics. JAMA: The Journal of the American Medical Association, 262(12), 1646–1652. https://doi.org/10.1001/jama.1989.03430120100029

50

References• Farren, C. K., Hill, K. P., & Weiss, R. D. (2012). Bipolar disorder and alcohol use disorder: A review. In Current Psychiatry Reports (Vol. 14, Issue 6, pp.

659–666). Springer. https://doi.org/10.1007/s11920-012-0320-9

• Geller, B., Reising, D., Leonard, H. L., Riddle, M. A., & Timothy Walsh, B. (1999). Critical review of tricyclic antidepressant use in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 38(5), 513–516. https://doi.org/10.1097/00004583-199905000-00012

• Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018). Ketamine for the treatment of addiction: Evidence and potential mechanisms. In Neuropharmacology (Vol. 142, pp. 72–82). Elsevier Ltd. https://doi.org/10.1016/j.neuropharm.2018.01.017

• Jones, J. L., Mateus, C. F., Malcolm, R. J., Brady, K. T., & Back, S. E. (2018). Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Frontiers in Psychiatry, 9(JUL), 277. https://doi.org/10.3389/fpsyt.2018.00277

• Keller, M. B., Lavori, P. W., Rice, J., Coryell, W., & Hirschfeld, R. M. (1986). The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: A prospective follow-up. American Journal of Psychiatry, 143(1), 24–28. https://doi.org/10.1176/ajp.143.1.24

• Levin FR & Hennessey G. (2004). Bipolar disorder and substance abuse. Biological Psychiatry, 56(10): 738-48.

• NESARC 2001-2002

• Nunes, E. v., & Levin, F. R. (2004). Treatment of Depression in Patients with Alcohol or Other Drug Dependence: A Meta-analysis. In Journal of the American Medical Association (Vol. 291, Issue 15, pp. 1887–1896). JAMA. https://doi.org/10.1001/jama.291.15.1887

• Pettinati, H. M., Oslin, D. W., Kampman, K. M., Dundon, W. D., Xie, H., Gallis, T. L., Dackis, C. A., & O’Brien, C. P. (2010). A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence. American Journal of Psychiatry, 167(6), 668–675. https://doi.org/10.1176/appi.ajp.2009.08060852

51

References• Salloum, I. M., Cornelius, J. R., Daley, D. C., Kirisci, L., Himmelhoch, J. M., & Thase, M. E. (2005). Efficacy of valproate maintenance in patients with

bipolar disorder and alcoholism: A double-blind placebo-controlled study. Archives of General Psychiatry, 62(1), 37–45. https://doi.org/10.1001/archpsyc.62.1.37

• Salloum, I. M., Douaihy, A., Cornelius, J. R., Kirisci, L., Kelly, T. M., & Hayes, J. (2007). Divalproex utility in bipolar disorder with co-occurring cocaine dependence: A pilot study. Addictive Behaviors, 32(2), 410–415. https://doi.org/10.1016/j.addbeh.2006.05.007

• SAMHSA, 2007

• Stedman, M., Pettinati, H. M., Brown, E. S., Kotz, M., Calabrese, J. R., & Raines, S. (2010). A Double-Blind, Placebo-Controlled Study With Quetiapine as Adjunct Therapy With Lithium or Divalproex in Bipolar I Patients With Coexisting Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 34(10), 1822–1831. https://doi.org/10.1111/j.1530-0277.2010.01270.x

• Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. NEJM, 2021, 384(2):140-153. doi:

10.1056/NEJMoa2020214.

• Zhang, J. J. Q., Fong, K. N. K., Ouyang, R. ge, Siu, A. M. H., & Kranz, G. S. (2019). Effects of repetitive transcranial magnetic stimulation (rTMS) on craving and substance consumption in patients with substance dependence: a systematic review and meta-analysis. In Addiction (Vol. 114, Issue 12, pp. 2137–2149). Blackwell Publishing Ltd. https://doi.org/10.1111/add.14753

52